Loading patent…
AssigneesGenzyme Corporation, University Health Network
InventorsShaf Keshavjee, Judith A. St. George, Mingyao Liu
Estimating the term…
Effective use of a TGF-β antagonist to treat or to prevent loss of transplant function is described herein. Use of a TGF-β antagonist is demonstrated to effectively prevent loss of organ function in a host due to chronic rejection in which TGF-β-mediated fibroproliferation is a characteristic. Expression in situ of a TGF-β antagonist in the form of a recombinant receptor, i.e., TGF-β type III receptor (TGFBIIIR) showed prevention of bronchiolitis obliterans in comparison to untreated controls in a rat lung transplant model. This provides an effective method for preventing or inhibiting chronic rejection of transplant organs such as lung, kidney, liver and heart in vertebrate hosts including human hosts.
A method for inhibiting chronic rejection of a transplant comprising administering to a transplant recipient an amount of a TGF-β antagonist effective to reduce TGF-β-mediated fibrosis in the transplant.
A method for inhibiting loss of transplant function in a recipient of such transplant comprising administering to said individual a pharmaceutically effective amount of a TGF-β antagonist.
Dependencies are inferred from the claim text.